Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
Clinical trial NCT00275431 · COMPLETED
Trial details
- NCT number
- NCT00275431
- Sponsor
- Ascenta Therapeutics
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2005-11-01
- Primary completion
- 2008-12-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.